Is VRDN a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Lumvoa launch and TED market share, with revenue (q1 2026) at ~$0.1M. The bear case rests on viridian is a newly commercial biotech with negligible trailing revenue and quarterly net losses above $100 million, so its valuation depends heavily on future sales that have not yet materialized. Analysts covering it are spread from $22.00 to $50.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Viridian is a newly commercial biotech with negligible trailing revenue and quarterly net losses above $100 million, so its valuation depends heavily on future sales that have not yet materialized. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $22.00, +13.6% from the $19.36 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Lumvoa launch and TED market share. Lumvoa is Viridian's first commercial product and its near-term value driver. The most optimistic analyst target on VRDN is $50.00, +158.3% from the $19.36 price. That figure is only reachable if this thesis works close to its best case.

Viridian is a newly commercial biotech with negligible trailing revenue and quarterly net losses above $100 million, so its valuation depends heavily on future sales that have not yet materialized. Lumvoa faces direct competition from Amgen's Tepezza, an entrenched incumbent that is also developing a subcutaneous formulation, and launch uptake, pricing, reimbursement, and physician adoption are all uncertain. The company is concentrated in thyroid eye disease, a rare-disease market, so any safety signal, slow launch, or competitive setback would weigh heavily. Pipeline programs like elegrobart and the FcRn portfolio carry clinical and regulatory risk, and continued losses could eventually require additional capital that dilutes shareholders. The most pessimistic published target is $22.00, +13.6% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Viridian Therapeutics (Nasdaq: VRDN) is a biopharmaceutical company focused on thyroid eye disease (TED), a rare autoimmune condition that causes eye bulging (proptosis) and double

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Lumvoa launch and TED market share) stalling in the reported numbers rather than in the narrative, the risk above (viridian is a newly commercial biotech with negligible trailing revenue and quarterly net losses above $100 million, so its valuation depends heavily on future sales that have not yet materialized) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Viridian is a biopharmaceutical company focused on thyroid eye disease (TED), a rare autoimmune condition that causes eye bulging and double vision. Its lead drug, Lumvoa (veligrotug), won FDA approval in June 2026, and it is developing additional TED and autoimmune candidates.

Lumvoa is Viridian's first commercial product, an intravenous anti-IGF-1R antibody approved in June 2026 for both active and chronic thyroid eye disease. In phase 3 trials it produced proptosis responder rates of roughly 70% in active and 56% in chronic disease versus single-digit placebo rates.

No. As of Q1 2026 Viridian had negligible revenue (about $0.1 million) and a net loss near $105 million, driven by roughly $78 million of R&D and $39 million of SG&A spending. It is a pre-profit biotech funding a new drug launch.